Empaveli

Chemical Namepegcetacoplan
Dosage FormInjection (subcutaneous; 1,080 mg/20 mL (54 mg/mL))
Drug ClassInhibitors
SystemBlood
CompanyApellis Pharmaceuticals, Inc
Approval Year2021

Indication

  • For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Last updated on 5/18/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Empaveli (pegcetacoplan) Prescribing Information2021Apellis Pharmaceuticals, Inc., Waltham, MA
Document TitleYearSource
Pegcetacoplan versus eculizumab in aroxysmal nocturnal hemoglobinuria. 2021New England Journal of Medicine